Coronary artery perforation during percutaneous intervention: incidence and outcome

Heart. 2002 Nov;88(5):495-8. doi: 10.1136/heart.88.5.495.

Abstract

Objective: To examine the clinical outcome of percutaneous coronary intervention where the procedure was complicated by vessel perforation.

Setting: Tertiary referral centre.

Methods: The procedural records of 6245 patients undergoing coronary intervention were reviewed. In 52 patients (0.8%) the procedure was complicated by vessel perforation, ranging from wire exit to free flow of contrast into the pericardial space. The majority of lesions treated were complex (37% type B, 59% type C) and 9 of 52 (17%) were chronic occlusions. Ten patients (19%) received abciximab. Four underwent rotational atherectomy (8%).

Results: In 28 of 52 patients (54%) the perforation was benign and managed conservatively without the development of haemodynamically significant sequelae. In 24 of 52 (46%) a significant pericardial effusion ensued requiring drainage. Of these 24 procedures 6 had involved the treatment of a chronic occlusion (25%). Eight of the 24 patients were referred for emergency bypass surgery (33%), 3 of whom died. Of the remaining 16 not referred for surgery, 3 died. Of the 10 procedures complicated by vessel perforation where abciximab had been administered, 9 (90%) led to pericardial tamponade. Latterly 2 vessel perforations were successfully treated by the deployment of a covered stent.

Conclusions: Coronary artery perforation with sequelae during intervention is rare--26 of 6245 (0.4%). This complication was seen in the treatment of chronic occlusions, which are therefore not risk-free procedures. The development of pericardial tamponade carries a high mortality. While prompt surgical intervention may be life saving, expertise in the use of covered stents may provide a valuable rescue option for this serious complication. Caution should be exercised where coronary perforation occurs and abciximab has been used.

MeSH terms

  • Abciximab
  • Adult
  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Antibodies, Monoclonal / adverse effects
  • Atherectomy, Coronary / adverse effects
  • Cardiac Tamponade / etiology
  • Cohort Studies
  • Coronary Stenosis / pathology
  • Coronary Stenosis / therapy*
  • Coronary Vessels / injuries*
  • Female
  • Humans
  • Immunoglobulin Fab Fragments / adverse effects
  • Male
  • Middle Aged
  • Pericardial Effusion / etiology
  • Platelet Aggregation Inhibitors / adverse effects
  • Prognosis
  • Prospective Studies
  • Rupture / etiology

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Abciximab